Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0IRKJU
ADC Name
AXL-183-N52Q-MMAE
Synonyms
AXL 183 N52Q MMAE
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 4 Indication(s)
Cervical cancer [ICD11:2C77]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Melanoma [ICD11:2C30]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
AXL-183-N52Q
  Antibody Info 
Antigen Name
Tyrosine-protein kinase receptor UFO (AXL)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 24.7
%
LCLC-103H cells
Lung large cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 24.70% (Day 18) Positive AXL expression (AXL+++/++)
Method Description
In the LCLC-103H xenograft model,therapeutic treatment with a single dose of 1 mg/kg in anti-tumor activity in the AXL-ADC panel.
In Vivo Model Lung cancer CDX model
In Vitro Model Lung large cell carcinoma LCLC-103H cells CVCL_1375
References
Ref 1 Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 2018 Feb;24(2):203-212.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.